Annual Prize Lecture 2024: Endogenous physiological mechanisms as basis for the treatment of obesity and type 2 diabetes.
2024 年年度獎講:內源性生理機制作為治療肥胖和 2 型糖尿病的基礎。
J Physiol 2024-11-09
Reflections on the discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directions.
GLP-1作為飽足激素的發現:對肥胖治療的意義和未來方向的反思。
Eur J Clin Nutr 2024-06-18
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.
肥胖中 GLP-1 生理學及基於促胰島素的藥物在慢性體重管理中的發展。
Nat Metab 2024-08-19
The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity.
基於 GLP-1 藥物的發現與發展,徹底改變了肥胖症的治療。
Proc Natl Acad Sci U S A 2024-09-19
Editorial: Potentials and Pitfalls in Targeting Glucagon-Like Peptide-1 (GLP-1) in the Management of Increasing Levels of Obesity.
編輯部:針對日益增加的肥胖水平,靶向胰高血糖素樣肽-1 (GLP-1) 的潛力與陷阱。
Med Sci Monit 2024-10-01
Targeting central pathway of Glucose-Dependent Insulinotropic Polypeptide, Glucagon and Glucagon-like Peptide-1 for metabolic regulation in obesity and type 2 diabetes.
針對葡萄糖依賴性胰島素促進多肽、胰高血糖素及胰高血糖素樣肽-1的中央通路,以進行肥胖和2型糖尿病的代謝調節。
Diabetes Obes Metab 2024-12-26